| Aug 21 |
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth
|
| Aug 14 |
Unicycive Therapeutics GAAP EPS of -$0.29
|
| Aug 14 |
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 17 |
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
|
| Jul 11 |
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
|
| Jul 10 |
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
|
| Jul 8 |
Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday
|
| Jul 1 |
Unicycive Therapeutics joins Russell Microcap Index
|
| Jul 1 |
Unicycive Therapeutics Joins Russell Microcap® Index
|
| Jun 25 |
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
|
